Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030003 | 0.92 | ALDH1A1 (0.47) | MYCALDH1A1SMN1; SMN2PPARAPROKR1 | |
| SCHEMBL4030020 | 0.90 | HPGD (0.48) | MYCALDH1A1SMN1; SMN2PROKR1CNR1 | |
| SCHEMBL4030726 | 0.86 | PROKR1 (0.57) | MYCALDH1A1PROKR1LMNARAB9A | |
| SCHEMBL4030825 | 0.86 | BCL9 (0.54) | MYCPROKR1 | |
| SCHEMBL4033727 | 0.85 | PPARA (0.61) | MYCALDH1A1SMN1; SMN2PPARAPOLB | |
| SCHEMBL4032390 | 0.83 | ALDH1A1 (0.50) | MYCALDH1A1SMN1; SMN2PROKR1POLB | |
| SCHEMBL4032391 | 0.83 | ALDH1A1 (0.50) | MYCALDH1A1SMN1; SMN2PROKR1POLB | |
| SCHEMBL4034835 | 0.83 | HPGD (0.48) | MYCALDH1A1SMN1; SMN2PROKR1CNR1 | |
| SCHEMBL4032162 | 0.80 | PPARA (0.51) | MYCALDH1A1SMN1; SMN2PPARAPOLB | |
| SCHEMBL4032605 | 0.78 | BCL9 (0.49) | MYCSMN1; SMN2PROKR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567493-B1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PROD INC (US) | 2009-03-18 | — | — | EP | disclosed |
| CN-100439337-C | Phenyl substituted piperidine compounds for use as PPAR activators | PFIZER PROD INC (US) | 2008-12-03 | — | — | CN | disclosed |
| US-20070281935-A1 | Use | PFIZER INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070232647-A1 | Use of Ppar Agonists to Treat Ruminants | GOETZE LEOPOLD F | 2007-10-04 | — | — | US | disclosed |
| US-20070191429-A1 | PPAR ACTIVATORS | PFIZER INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7199243-B2 | Piperidine compounds useful as PPAR activators | PFIZER INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1765320-A2 | USE OF PPAR AGONISTS TO TREAT RUMINANTS | Pfizer Products Incorporated (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1753426-A2 | RUMINANT TREATMENTS | Pfizer Products Incorporated (US) | 2007-02-21 | — | — | EP | disclosed |
| CN-1717389-A | Phenyl substituted piperidine compounds for use as PPAR activators | PFIZER PROD INC (US) | 2006-01-04 | — | — | CN | disclosed |
| WO-2005115389-A2 | SPECIFIC PPAR AGONISTS FOR TREATING NEGATIVE ENERGY BALANCE | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005115369-A2 | USE OF PPAR AGONISTS TO TREAT RUMINANTS | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-1567493-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | Pfizer Products Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040157885-A1 | PPAR activators | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| WO-2004048334-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191429-A1 | PPAR ACTIVATORS | PPARA, PPARG, PPARD | MYC 4374/4885ALDH1A1 2006/4885SMN1; SMN2 4752/4885 |
| US-20040157885-A1 | PPAR activators | PPARA, PPARG, PPARD | MYC 4374/4885ALDH1A1 2006/4885SMN1; SMN2 4752/4885 |
| US-20070281935-A1 | Use | ALPP, CPT1A, PIGS | MYC 1298/4885ALDH1A1 1989/4885SMN1; SMN2 2492/4885 |
| US-20070232647-A1 | Use of Ppar Agonists to Treat Ruminants | PPARG, PPARD, PPARA | MYC 800/4885ALDH1A1 2089/4885SMN1; SMN2 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.